Skip to main
HUM
HUM logo

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 37 analyst ratings
Buy
Strong Buy 19%
Buy 27%
Hold 51%
Sell 3%
Strong Sell 0%

Bulls say

Humana demonstrates a positive outlook due to stable cost trends observed from the third to fourth quarter of 2024, with anticipated improvements in adjusted EPS driven by potential advancements in star ratings for Medicare contracts. The company is positioned for growth through ongoing investments aimed at enhancing clinical excellence and achieving margins in group Medicare Advantage, with a solid competitive standing supported by its above-industry star rating profile. Additionally, management’s focused efforts on Stars recovery initiatives, coupled with strategic investments in pricing and operational improvements, point toward long-term sustainable growth for the company.

Bears say

Humana's outlook appears negative primarily due to a missed opportunity in achieving its Star ratings, which has led to heightened margin pressure and concerns over medical loss ratio (MLR) stability. Projections indicate that the timeline for reaching target Medicare Advantage (MA) margins has shifted from 2027 to 2028, creating further uncertainty surrounding the company’s future profitability. Additionally, ongoing elevated investments aimed at enhancing clinical excellence are expected to persist beyond 2025, suggesting that the financial improvements may take longer than previously anticipated.

Humana (HUM) has been analyzed by 37 analysts, with a consensus rating of Buy. 19% of analysts recommend a Strong Buy, 27% recommend Buy, 51% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Buy based on their latest research and market trends.

According to 37 analysts, Humana (HUM) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $318.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $318.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.